Novo Nordisk's Wegovy pill leads GLP-1 weight loss market, outpacing Eli Lilly's Foundayo launch.

Novo Nordisk's Wegovy pill has rapidly expanded the GLP-1 weight loss drug market since its U.S. launch in January, doubling patient intake for telehealth providers and outperforming Eli Lilly's Foundayo pill introduced three months later. Wegovy's success is attributed to strong marketing, lower price, and high efficacy, attracting many new patients who prefer pills over injections. Eli Lilly is still building awareness for Foundayo, which has seen modest early uptake but shows potential for growth over time. Investors will watch Novo's upcoming earnings and market expansion plans, while both companies aim to capture a broader patient base with oral GLP-1 drugs.